[Effect of different doses of atorvastatin on adhesion molecules of the patients undergoing percutaneous coronary intervention].
OBJECTIVE
To determine the effect of different doses of atorvastatin on the serum soluble intercellular adhesion molecules-1 (sICAM-1) in patients undergoing percutaneous coronary intervention (PCI).


METHODS
The study consisted of 38 patients with unstable angina and 10 patients with old infarction who underwent elected PCI for stenotic lesions of the coronary artery. Patients were randomly assigned to either aggressive group or conventional one. After PCI the patients took atorvastatin 20 mg per day or 10 mg per day. Blood lipid profile was examined before, and 3 months after the PCI. SICAM-1 was examined before the PCI, 48 hours and 3 months after the PCI.


RESULTS
The total cholesterol and LDL-Cholesterol 3 months after the PCI in the 2 groups were lower than those before the PCI (P<0.01). The aggressive group showed greater reduction in concentrations of TC and LDL-C than the conventional group (P<0.01). The changes in concentrations of HDL-C between pre-PCI and 3 months after the PCI and TG were not obvious (P>0.05). sICAM-1 in the 2 groups 48 hours after the PCI significantly higher than that before the PCI (P<0.01). But sICAM-1 in the 2 groups 3 months after the PCI significantly lower than that before the PCI (P<0.01 or P<0.05). The aggressive group showed greater reduction than the conventional group (P<0.01). TC and LDL-C were positively correlated with sICAM-1(r=0.2413, r=0.2691, all P<0.05).


CONCLUSIONS
Atorvastatin 20 mg per day reduces TC, LDL-C, and sICAM-1 to a greater extent than atorvastatin 10 mg per day. The effect on sICAM-1 is partly related to reduce lipid profile.
Ma
Qi-lin
QL
Department of Cardiology, Xiangya Hospital, Central South Univevsity, Changsha 410008, China.
Mo
Long
L
Yang
Tian-lun
TL
Pu
Xiao-qun
XQ
Wu
Sheng-bin
SB
Xie
Wei
W
Zeng
Xiao-lin
XL
Chen
Fan
F
Chen
Fang-ping
FP
D000368:Aged; D000069059:Atorvastatin; D005260:Female; D006538:Heptanoic Acids / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood*; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention; D011758:Pyrroles / Q000008:administration & dosage* / Q000627:therapeutic use
D006538:Heptanoic Acids; D011758:Pyrroles; D018799:Intercellular Adhesion Molecule-1; D000069059:Atorvastatin